Journal of Nuclear Medicine

Papers
(The H4-Index of Journal of Nuclear Medicine is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Practicing Medicine in Wartime Ukraine229
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study147
Positron Range Correction Helps Enhance the Image Quality of Cardiac82Rb PET/CT135
Serial [ 18 F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair123
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions106
Quantitative Deauville Scoring to Uncover Prognostic Information from 18F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial102
Delta-like Ligand 3–Directed 225 Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models97
Impact of Single-Time-Point Estimates of177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles93
Localized In Vivo Prodrug Activation Using Radionuclides90
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [15O]H2O PET Imaging79
Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [ 177 Lu]Lu-PSMA Therapy Injections Through Serial78
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States73
Preclinical Evaluation of226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy70
CCK2Receptor Ligand [68Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [68Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer70
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green68
Diagnostic Performance of [ 18 F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study67
Biochemical Recurrence–Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging66
Interspecies Variability in Biodistribution and PET Imaging Performance of [18F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer66
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer65
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression64
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals64
Quantitative Spatial Profiling of Antibody Delivery and Target Engagement Using Optically Labeled Antibodies63
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer63
Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies61
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study61
[ 177 Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial60
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of99mTc and188Re Theranostic Agents for Prostate Cancer60
Nuclear Medicine AI in Action: The Bethesda Report (AI Summit 2024)59
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging58
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [18F]PSMA-1007 PET/CT57
68Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines57
177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial57
Precision Medicine Clinical Trials57
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses56
161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with177Lu in Preclinical Models of Ovarian Cancer56
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)56
The Role of Molecular Imaging in Precision Oncology55
Artificial Intelligence–Powered Quantification of Flortaucipir PET for Detecting Tau Pathology55
Preclinical Characterization of the Tau PET Tracer [18F]SNFT-1: Comparison of Tau PET Tracers55
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care55
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?54
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)54
Brain Metabolic Activity Measured by [ 18 F]FDG PET/CT Predicts Survival in Patients with Advanced Non–Small Cell Lung Cancer54
Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals”52
Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer51
Challenges with177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice51
177Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?51
Translation of Intraoperative Molecular Imaging for Clinical Use50
Intrapatient 16α-[18F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor–Positive Metastatic Breast49
3.1125659942627